{
  "symbol": "XRN-PB",
  "company": "Chiron Real Estate Inc.",
  "generated_at": "2026-06-24T07:36:54.444Z",
  "event_count": 4,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-05-21T22:32:12.643Z",
      "summary": "XRN-PB is the Series B Cumulative Redeemable Preferred Stock (NYSE: XRN PrB) of Chiron Real Estate Inc., a small-cap healthcare REIT that recently rebranded from Global Medical REIT. The investigation trigger cited 3 Form 4 filings in 14 days, but querying both XRN-PB and parent ticker XRN returned zero Form 4 transaction records — the trigger signal appears spurious or based on unverified sources. The preferred stock trades at a discount to stated book value (P/B 0.82x), pays an attractive ~5.76% dividend yield, and has no listed options market, making it unsuitable for income-option strategies like CSPs or CCs but potentially interesting as a direct fixed-income-equivalent hold. Recent catalysts include three SHOP community acquisitions ($425M aggregate) from Silverstone Senior Living, a new Maewyn Capital Partners $100M preferred equity commitment (with Maewyn's founder now appointed to the board), and the company's broader strategic pivot into seniors housing.",
      "verdict": "no_anomaly",
      "confidence": 3,
      "tool_calls": 18,
      "walltime_min": 13,
      "debug_path": "dossiers/2026-05-21-XRN-PB.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-13T23:53:39.968Z",
      "skip": true,
      "reason": "Score is 12. Fails liquidity and dilution/concentration anti-signals while quality metrics are weak (11.2x net debt/EBITDA, negative EPS, shrinking margins), and the preferred instrument lacks an options market. The $370k insider cluster is insufficient to offset the fundamental leverage and SHOP operational pivot risk.",
      "score": 12,
      "breakdown": {
        "smart_money": 7,
        "options_flow": 0,
        "catalyst": 5,
        "mispricing": 0,
        "quality": 0,
        "technical": 0
      },
      "debug_path": "drafts/2026-05-13-XRN-PB.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-13T23:52:51.250Z",
      "summary": "XRN is a small-cap healthcare/senior-housing REIT in active transformation, pivoting from net-lease medical outpatient to seniors housing operating properties (SHOP). Four C-suite insiders made open-market purchases of common stock in May 2026 at $33.49-$34.00/share — roughly 35-40% above the current XRN-PB price of $24.50. The company simultaneously announced a $425M triple-acquisition from Silverstone Senior Living funded partly by a new $100M Maewyn Capital preferred equity commitment (Series C). XRN is deeply leveraged (debt/equity ~130%), loss-making on common EPS, and the pivot into SHOP introduces meaningful operational risk. The insider cluster is technically bullish but those purchases were in common stock; the XRN-PB preferred trades at a discount to its stated liquidation preference of $25 with an 8.9% annualized yield — the income thesis is real, but asymmetric upside requires a successful acquisition integration that resets earnings power.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 26,
      "walltime_min": 16,
      "debug_path": "dossiers/2026-05-13-XRN-PB.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-12T22:52:58.611Z",
      "summary": "Chiron Real Estate is a sub-$500M medical REIT executing an aggressive strategic pivot from net-lease outpatient facilities into seniors housing operating properties (SHOP). Five insiders — including the CEO, CFO, COO, and two directors — purchased open-market common stock within a 48-hour window in mid-May 2026 totaling approximately $320K, representing genuine conviction above normal director-fee compensation. However, the underlying story complicates the thesis: four consecutive quarterly EPS/FFO misses (most recent -13x), an unresolved negative forward P/E (-56x), and a balance sheet already stretched with ~$677M debt undertaking $425M in new SHOP acquisitions funded via $100M preferred equity dilution. The stock is fully valued on healthcare REIT comparables and shows no technical edge. Options flow is bearish (put/call ratio 2:1), consistent with hedging of near-term earnings and closing risk on the Silverstone deals.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 22,
      "walltime_min": 26,
      "debug_path": "dossiers/2026-05-12-XRN-PB.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "XRN-PB",
    "call": "HOLD",
    "confidence": 5,
    "score": 4,
    "factors": {
      "above_50dma": "+1",
      "momentum_flat": "0 (-3.2%)",
      "rsi_neutral": "0 (59.5)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (17d ago)",
      "near_52w_high": "+1 (-1.2% from high)"
    },
    "summary": "HOLD (score +4) · 12-1 mom -3.2% · RSI 59.5 · above_50_only · -1.2% from high",
    "last_close": 25.05,
    "one_month_ago_close": 24.03,
    "twelve_month_ago_close": 24.82,
    "twelve_one_momentum_pct": -3.18,
    "rsi_14": 59.5,
    "ma_stack": "above_50_only",
    "from_period_high_pct": -1.22,
    "period_high": 25.36,
    "price_targets": {
      "bear": 17.75,
      "fair": 24.86,
      "bull": 29.16,
      "bear_return_pct": -29.1,
      "fair_return_pct": -0.8,
      "bull_return_pct": 16.4,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": null,
        "target_mean": null,
        "target_high": null,
        "analyst_count": null
      }
    },
    "generated_at": "2026-06-24T07:36:54.441Z"
  }
}